EMD 525797

BIOLOGICAL3 trials

Sponsors

Merck KGaA, Darmstadt, Germany, EMD Serono

Conditions

Bone MetastasesColorectal and Ovarian Cancer Patients With Liver MetastasesProstate CancerProstate Cancer Metastatic

Phase 1

EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases

CompletedNCT00848510

Merck KGaA, Darmstadt, GermanyColorectal and Ovarian Cancer Patients With Liver Metastases

Start: 2009-02-28End: 2013-11-30Updated: 2015-12-14

A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer

CompletedNCT00958477

Merck KGaA, Darmstadt, GermanyBone Metastases, Prostate Cancer

Start: 2008-10-31End: 2011-03-31Updated: 2017-08-02

Phase 2

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

CompletedNCT01360840

EMD SeronoProstate Cancer Metastatic

Start: 2011-04-30End: 2014-07-31Updated: 2015-12-14

Related Papers

Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer.

2016-02-0253 citations

Primary outcomes of the placebo-controlled phase 2 study PERSEUS (NCT01360840) investigating two dose regimens of abituzumab (DI17E6, EMD 525797) in the treatment of chemotherapy-naive patients (pts) with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2014-05-203 citations

A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy.

2013-06-0634 citations